blood biomarkers

Blood biomarkers in ageing and dementia

(Leader: Géraldine Poisnel).


There is an increasing emphasis on developing blood biomarkers:

  1. for diagnosis and prediction of dementia,

  2. to identify underlying pathophysiological mechanisms, and

  3. to serve as intermediate outcome measures to monitor response to interventions.

The Age-Well study offers a unique set of complementary assessments including blood markers (general health, emotions, stress, ageing and AD) but also detailed cognitive, sleep, and neuroimaging measures before and after an 18-month period of intervention in 137 individuals (>65 years old). This rich database gives us the opportunity to study the meaning and relevance of blood biomarkers (compared to the other well-defined biomarkers such as neuroimaging), but also to obtain specific composite measures that appear as particularly promising. This is the case for the allostatic load, a biological composite score that aims to capture the overall physiological wear-and-tear of the body triggered by the repeated activation of compensatory physiological mechanisms as a response to physical, psychological, psychosocial life-long stress. We will be in an advantageous position to investigate the potential of this measure for diagnosis, prognosis and disease pathophysiology and treatment assessment.